CORDIS
EU research results

CORDIS

English EN
Evaluation of phage therapy for the treatment of Escherichia coli and Pseudomonas aeruginosa burn wound infections (Phase I-II clinical trial)

Evaluation of phage therapy for the treatment of Escherichia coli and Pseudomonas aeruginosa burn wound infections (Phase I-II clinical trial)

Objective

Sepsis is the major problem of large burn patients and a predominant cause of death. The burn wound pathology, combined to a global intensive use of antibiotics (ATB), put patients at high risk of suffering from multidrug resistant (MDR) infections, notably carried out by the Gram-negative bacteria species: Pseudomonas aeruginosa or Escherichia coli. But the last Gram- ATB is more than 20 years old and impeded by spread out exponential resistance. New ATB with genuine mode of action to target current resistant types are out of scope. In this context, MDR Gram- infections are becoming orphan pathologies without treatment. Fighting MDR in burn trauma is becoming an urgent medical need through innovation.

PHAGOBURN is focused on a highly promising alternative to ATB: phage therapy. Bacteriophages are viruses that specifically infect and kill bacteria during their replicative cycle. The main objective of the project is to assess the safety, effectiveness and pharmacodynamics of two therapeutic phage cocktails to treat either E. coli or P. aeruginosa burn wound infections. To reach that goal, a combined Phase I/II multicentric clinical trial will be carried out in 3 EU countries (France, Belgium, Switzerland), by different hospital burn units. Prior to that, a GMP bioproduction process will be implemented to produce both drug products according to current EMA standards. Meanwhile, the production process and the trial results will provide basis for an optimization of current regulatory guidelines.

PHAGOBURN is coordinated by the French Ministry of Defence. The Consortium also includes the following partners: Pherecydes (French SME) and Clean Cells (French SME) for the GMP bioproduction of drug products, CHU Vaudois (CH) burn wards, as well as the Royal Military Academy of Belgium (Queen Astrid).
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

MINISTERE DE LA DEFENSE

Address

Rue Saint Dominique, 14
75007 Paris

France

Activity type

Public bodies (excluding Research Organisations and Secondary or Higher Education Establishments)

EU Contribution

€ 210 236,48

Administrative Contact

Alexis Martin (Mr.)

Participants (4)

Sort alphabetically

Sort by EU Contribution

Expand all

PHERECYDES PHARMA SA

France

EU Contribution

€ 1 988 575,86

CLEAN CELLS SAS

France

EU Contribution

€ 1 259 087,97

ECOLE ROYALE MILITAIRE - KONINKLIJKE MILITAIRE SCHOOL

Belgium

EU Contribution

€ 218 490,83

CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS

Switzerland

EU Contribution

€ 162 030,86

Project information

Grant agreement ID: 601857

Status

Closed project

  • Start date

    1 June 2013

  • End date

    28 February 2017

Funded under:

FP7-HEALTH

  • Overall budget:

    € 4 920 435,99

  • EU contribution

    € 3 838 422

Coordinated by:

MINISTERE DE LA DEFENSE

France